HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yokoyama, I. Articles by Yazaki, Y. Search for Related Content PubMed PubMed Citation Articles by Yokoyama, I. Articles by Yazaki, Y.

Insulin Action on Heart and Skeletal Muscle FDG Uptake in Patients with Hypertriglyceridemia

Departments of Cardiovascular Medicine, Metabolic Diseases, Radiology and Gastroenterology, University of Tokyo, Tokyo, Japan

Correspondence: For correspondence or reprints contact: Ikuo Yokoyama, MD, Department of Cardiovascular Disease, University of Tokyo, 7-3-1 Hongoh Bunkyo-ku, Tokyo 113-8655, Japan.

ABSTRACT

Abnormal heart and skeletal muscle ¹⁸F-fluorodeoxyglucose (FDG) uptake in patients with insulin resistance has been demonstrated. Although the existence of whole-body insulin resistance has been reported in hypertriglyceridemics, its specific role in heart and skeletal muscle FDG uptake in hypertriglyceridemics has not been clarified. Methods: We compared heart and skeletal muscle FDG uptake using PET and the whole-body glucose disposal rate (GDR) during insulin clamping in 17 hypertriglyceridemics and 12 age-matched control subjects to increase our knowledge of whole-body insulin resistance and its relationship to heart and skeletal muscle FDG uptake in hypertriglyceridemics. Results: GDR was significantly reduced in hypertriglyceridemics compared with control subjects (4.50 ± 1.37 mg/min/kg versus 10.0 ± 2.97 mg/min/kg, P = 0.00001), as were the skeletal muscle FDG K_i, = (k₁, x k₃)/(k₂ + k₃) (SFK_i: 0.007 ± 0.003 mL/min/g versus 0.018 ± 0.01 mL/min/g, P = 0.0001) and skeletal muscle FDG uptake ([SMFU] 0.725 ± 0.282 mg/min/100 g versus 1.86 ± 1.06 mg/min/100 g, P = 0.00023). However, myocardial FDG K_i (MFK_i) tended to be reduced in hypertriglyceridemics compared with that in control subjects (0.062 ± 0.017 mL/min/g versus 0.068 ± 0.015 mL/min/g), but the difference was statistically insignificant (P = 0.3532). Moreover, myocardial FDG uptake (MFU) in hypertriglyceridemics (6.47 ± 1.72 mg/min/100 g) tended to be reduced compared with that in control subjects (6.97 ± 1.73 mg/min/100 g), but the difference was statistically insignificant (P = 0.4485). GDR was significantly correlated with SFK_i (r = 0.69, P = 0.0022), SMFU (r = 0.612, P = 0.009), MFK_i (r = 0.57, P = 0.0174) and MFU (r = 0.505, P = 0.0385) in hypertriglyceridemics. Conclusion: Both heart and skeletal muscle glucose utilization were related to insulin resistance in hypertriglyceridemics. However, the less severe reduction in MFU (compared with SMFU) suggests that myocardium may have a mechanism to oppose insulin resistance in hypertriglyceridemics.

Key Words: insulin resistance • hypertriglyceridemia • fluorodeoxyglucose • PET • heart and skeletal muscle glucose metabolism

This article has been cited by other articles:

				L. Slimani, V. Oikonen, K. Hallsten, N. Savisto, J. Knuuti, P. Nuutila, and P. Iozzo Exercise Restores Skeletal Muscle Glucose Delivery But Not Insulin-Mediated Glucose Transport and Phosphorylation in Obese Subjects J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3394 - 3403. [Abstract] [Full Text] [PDF]

				A. Bertoldo, P. Peltoniemi, V. Oikonen, J. Knuuti, P. Nuutila, and C. Cobelli Kinetic modeling of [18F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E524 - E536. [Abstract] [Full Text] [PDF]

				I. Yokoyama, K. Yonekura, T. Moritan, M. Tateno, T. Momose, K. Ohtomo, Y. Inoue, and R. Nagai Troglitazone Improves Whole-Body Insulin Resistance and Skeletal Muscle Glucose Use in Type II Diabetic Patients J. Nucl. Med., July 1, 2001; 42(7): 1005 - 1010. [Abstract] [Full Text] [PDF]